Rosiglitazone limited the accumulation of early MDSCs and Tregs but increased circulating CD8+ T cells and intratumoral CD4+ and CD8+ T cells to change tumor-associated immunosuppressive mediators, thereby enhancing the effect of gemcitabine [198]. Here, CD8A is linked to neoplasm.